Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denocabtagene Ciloleucel - Beijing Yongtai Ruike Biotechnology Company

Next Previous
X
Search
Drug Profile

Denocabtagene Ciloleucel - Beijing Yongtai Ruike Biotechnology Company

Alternative Names: CAR-T-19-D2; CAR-T-19-DNR; Dinorencel; RC19-D2

Latest Information Update: 21 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Yongtai Ruike Biotechnology
  • Developer Beijing Yongtai Ruike Biotechnology; Immunotech Biopharm
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma

Most Recent Events

  • 05 Sep 2023 Phase-I clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater, Recurrent) in China (Parenteral, Injection) (NCT06047197)
  • 31 Mar 2023 NMPA approves clinical trial application for denocabtagene ciloleuce in Diffuse large B cell lymphoma
  • 28 Dec 2022 China's NMPA approves IND application for denocabtagene ciloleucel in Diffuse large B cell lymphoma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top